Immunomodulatory agents in mantle cell lymphoma
Mené sur 254 patients atteints d'un lymphome à cellules du manteau récidivant ou réfractaire, cet essai international de phase II évalue l'efficacité, du point de vue de la survie sans progression, et la toxicité du lénalidomide
Mantle cell lymphoma is a rare B-cell non-Hodgkin lymphoma that predominantly afflicts people in the seventh and eighth decades of life. Although historically considered an aggressive rather than indolent lymphoma, the disease at presentation might be either, with widely disparate clinical and biological characteristics and multifarious tumour proliferation rates that are predictive of outcome.1 It is a molecularly intriguing disease in which B-cell receptor signalling plays a crucial part in pathogenesis and presents many interesting therapeutic targets for novel drug development.
The Lancet Oncology , commentaire, 2015